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A b s t r A c t
Growing evidence suggests that atrial fibrillation (AF), in addition to its known 
thromboembolic risk, is a risk factor for significant cognitive impairment via several 
pathways, further contributing to morbidity and mortality. Whether anticoagulation, 
rhythm control strategies and other interventions aiming at preventing thromboem-
bolic events and ameliorating the clinical outcome of AF patients, may also have a 
beneficial effect on long-term cognitive function, remains to be seen in future studies.
I N t r O D U c t I O N
Atrial fibrillation (AF) is the commonest arrhythmia (1-2%) in the general popula-
tion, while due to its age-dependency its incidence may exceed 8-10% in the elderly, 
conferring considerable morbidity and mortality related to cardiovascular effects and 
thromboembolic complications, notably stroke.1,2 Oral anticoagulants for prevention of 
strokes and antiarrhythmic drugs for rate and/or rhythm control are the cornerstone of 
contemporary management, whereas evolving transcatheter ablation techniques play 
an increasingly important role.3
Mild cognitive impairment, initially defined as isolated memory deficit and later 
ascribed an expanded definition that includes different cognitive domains, can precede 
the development of dementia.4 Increasing evidence shows that AF is a risk factor for 
significant cognitive impairment in patients with and without a manifest stroke via 
a plethora of pathways (Table 1), further contributing to morbidity and mortality.5-8 
Atrial fibrillation has also been associated with conversion of cognitive impairment to 
full dementia.4 Furthermore, previously undiagnosed AF should be suspected upon 
the emergence of cognitive decline associated with cryptogenic and/or silent strokes. 
Recent guidelines indicate that screening for AF should be undertaken with pulse 
taking and/or electrocardiography or rhythm monitoring in patients aged >65 years.9 
The recently appreciated association of AF with cognitive decline should also lead to 
the concept of cognitive screening10 and rhythm monitoring in the aforementioned 
populations (Fig. 1).5 Although dementia and AF are common comorbidities in stroke 
patients, AF appears to have a potential role in cognitive impairment prior to a first 
stroke. Whether anticoagulation, rhythm control strategies and other interventions 
aiming at preventing thromboembolic events and ameliorating the clinical outcome 
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FIGUrE 1. A suggested algorithm for screening for atrial fibrillation (AF) and/or mild cognitive impairment (MCI). ECG = elec-
trocardiogram; LAA = left atrial appendage; MRI = magnetic resonance imaging; NOACs = non-vitamin K oral anticoagulants; 
PVI = pulmonary vein isolation (via radiofrequency or cryoballoon ablation); VKA = vitamin K antagonists; VR = ventricular rate 
* Rapid Cognitive Screen (RCS) for Mild Cognitive Impairment (MCI).
(0-5 = dementia; 6-7 = MCI; 8-10 = normal):44 
● Recall 5 objects (Apple, Pen, Tie, House, Car) / Recall objects after clock drawing (5 points).
● Clock Drawing (Draw with time at 10 minutes to 11 o’clock) (4 points).
● Insight: Jill was a very successful stockbroker. She made a lot of money on the stock market. She then met Jack, a devastatingly 
handsome man. She married him and had 3 children. They lived in Chicago. She then stopped work and stayed at home to bring up 
her children. When they were teenagers, she went back to work. She and Jack lived happily ever after. What country did they live 
in? (1 point).
** Thromboembolic / hemorrhagic risk commensurate with CHA2DS2-VASc / HAS-BLED scores, respectively.
tAbLE 1. Mechanisms and Factors Implicated in Cognitive Impairment Associated With Nonvalvular Atrial Fibrilla-
tion (AF) 
• Silent (subclinical) brain infarction due to microembolization of small thrombi emanating from the fibrillating left atrium in under-
anticoagulated patients or from advanced aortic atherosclerotic lesions or 
• silent cerebral microbleeds in over-anticoagulated patients
• loss of brain volume (brain atrophy)/lower volume of gray and white matter attributed to increased comorbidity and cerebral micro-
infarcts or microembolisms with subsequent brain atrophy in the AF population
• cerebral hypoperfusion, attributable to beat-to-beat variation in stroke volume. Patients with persistent/permanent AF may have more 
cerebral hypoperfusion than those with only paroxysmal AF, explaining the finding of greater brain atrophy encountered in patients 
with persistent-permanent AF/low or high ventricular rate response (<50/>90 bpm) is predictive of dementia in the presence but not 
in the absence of AF
• altered hemostatic function in patients with AF who develop dementia / higher D-dimer, prothrombin fragment 1+2 and thrombin-
antithrombin complexes levels / increased thrombin generation and fibrin turnover in individuals with AF and dementia compared with 
those without dementia 
• ? vitamin K deficiency in patients on vitamin K antagonists contributing to cognitive dysfunction, due to the potential role of vitamin K 
in brain physiology and a suggestion that its deficiency may induce cognitive decline 
• systemic inflammatory mechanisms as indicated by increased inflammatory markers correlating with neurocognitive functions and loss 
of brain volume
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of AF patients, may also have a beneficial effect on long-term 
cognitive function remains to be seen in future studies.
s t U D I E s  O F  c O G N I t I v E  I m p A I r m E N t  
I N  A t r I A L  F I b r I L L A t I O N
According with a cross-sectional Swedish study based on a 
cohort of 952 community-living men, aged 69 to 75 years, men 
with AF (n=44) had lower mean adjusted cognitive z scores 
than men without AF (P=0.0003).11 The exclusion of stroke 
patients or adjustments for 24-hour diastolic blood pressure 
and heart rate, diabetes, and ejection fraction did not change 
this relationship. Men with AF who were treated with digoxin 
(n=27) performed markedly better than those without treat-
ment (n=9; P=0.0005). Thus, this study demonstrated an as-
sociation between AF and low cognitive function independent 
of stroke, high blood pressure, and diabetes. 
A Framingham Study including 1011 men (mean age of 
61 years) free of clinical stroke and dementia indicated that 
those with (n=59) vs those without (n=952) AF at 8 months 
after the AF surveillance period exhibited significantly lower 
mean levels of cognitive performance.12
In a cross-sectional evaluation of 122 stroke-free individu-
als with AF compared with 563 individuals aged 37-84 years 
without AF, stroke-free individuals with AF performed signifi-
cantly worse in tasks of learning and memory (P <0.01) as well 
as attention and executive functions (P <0.01).13 There was 
also a trend (P=0.062) towards worse performance in learning 
and memory tasks in patients with chronic as compared with 
paroxysmal AF. Corresponding to the memory impairment, 
hippocampal volume on magnetic resonance imaging (MRI) 
was reduced in patients with AF. The authors concluded that 
even in the absence of manifest stroke, AF is a risk factor for 
cognitive impairment and hippocampal atrophy.
A post-hoc analysis of 2 randomized controlled trials 
involving 31,506 patients (aged 66.5 years) and evaluat-
ing the efficacy of treatment with ramipril plus telmisartan 
(ONTARGET) or telmisartan alone (TRANSCEND) in 
reducing cardiovascular disease, indicated that AF was pre-
sent at baseline in 1016 participants (3.3%) and developed 
during follow-up (median 56 months) in an additional 2052 
participants (6.5%).14 Atrial fibrillation was associated with an 
increased risk of cognitive decline (hazard ratio - HR 1.14), 
new dementia (HR 1.30), loss of independence in performing 
activities of daily living (HR 1.35) and admission to long-term 
care facilities (HR 1.53), regardless of having a stroke or not, 
or receiving antihypertensive drugs. The authors concluded 
that cognitive and functional decline are consequences of AF, 
even in the absence of overt stroke.
Among 270 individuals, 180 patients with AF (90 paroxys-
mal and 90 persistent) and 90 controls, at least 1 area of silent 
cerebral ischemia on MRI was present in 80 patients (89%) 
with paroxysmal AF, 83 (92%) with persistent AF, and 41 
(46%) controls (p <0.01).15 The number of areas of silent cer-
ebral ischemia per subject was higher in patients with persistent 
AF than in those with paroxysmal AF (41.1±28.0 vs. 33.2±22.8, 
p = 0.04). Cognitive performance was significantly worse in 
patients with persistent and paroxysmal AF than in controls. 
A recent prospective observational study evaluated the 
prevalence of prestroke cognitive impairment in 788 stroke 
patients (69.5% ischemic strokes, 21.3% transient ischemic at-
tacks, and 9.1% hemorrhagic strokes), and examined whether 
AF was associated with prestroke cognitive impairment.16 
Prestroke cognitive impairment was detected in 96 (12.5%) 
patients. Of these, 33 patients (4.3%) were demented before 
the actual stroke event. AF was independently associated 
with prestroke cognitive impairment. The authors concluded 
that patients with an acute stroke frequently show a history of 
cognitive impairment before the event; AF is independently 
associated with prestroke cognitive impairment. 
According to a longitudinal analysis in the Cardiovascular 
Health Study, a community-based study of 5,150 men and 
women aged ≥65 years, who did not have AF or a history of 
stroke at baseline, 552 (10.7%) developed incident AF during a 
mean follow-up of 7 years.17 Cognitive function was tested with 
use of the Modified Mini-Mental State Examination (3MSE), 
which is a general screening tool assessing memory, orienta-
tion, calculation, and verbal fluency. Scores on the 3MSE 
range from zero (worst) to 100 (best) with a cutoff of <78 
points for dementia screening. Mean 3MSE scores declined 
faster after incident AF compared with no prior AF, e.g. the 
predicted 5-year decline in mean 3MSE score from age 80 to 
age 85 was 26.4 points for individuals without a history of AF, 
but was 210.3 points for those experiencing incident AF at age 
80, a 5-year difference of 23.9 points. The authors concluded 
that in the absence of prior stroke, people with incident AF are 
likely to reach thresholds of cognitive impairment or dementia 
at earlier ages than people with no history of AF. 
A recent Australian prospective substudy of a multicenter 
randomised trial of an AF-specific disease management in-
tervention (the Standard versus Atrial Fibrillation spEcific 
managemenT studY; SAFETY) examined the incidence of 
mild cognitive impairment among 260 patients with chronic 
AF, aged 72±11 years (53% men, mean CHA2DS2-VASc 
score 4±2) and sought to identify predictors of this cognitive 
dysfunction.18 A total of 169 patients (65%) were found to have 
mild cognitive impairment at baseline with multiple deficits 
in cognitive domains, most notably in executive functioning, 
visuospatial abilities and short-term memory. Predictors of 
impaired cognition were lower education level (odds ratio - OR 
5-6), higher CHA2DS2-VASc score (OR 1.46) and prescribed 
digoxin (OR 2.19). The authors concluded that mild cognitive 
impairment is highly prevalent among older high-risk patients 
hospitalized with AF. 
Even in patients with heart failure having their own reasons 
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for cognitive decline, the occurrence of AF further exacerbates 
cognitive dysfunction. According to a recent study, among 
187 patients with heart failure,19 those with AF (32.1%) ex-
hibited worse global cognition, memory, and cerebral blood 
flow velocity of the middle cerebral artery relative to patients 
without AF, above and beyond the effects that could be as-
cribed to heart failure severity and other demographic and 
medical factors. Partial correlations controlling for possible 
confounds showed that decreased blood flow velocity of the 
middle cerebral artery predicted worse cognition in multiple 
domains in the overall sample (r=0.13 to 0.15, P <0.05) and 
in the subgroup of heart failure patients with AF (r=0.26 to 
r=0.28, P <0.05), but not among heart failure patients without 
AF. The authors concluded that AF exacerbates cognitive 
deficits in heart failure, possibly through its association with 
decreased cerebral perfusion. 
A metaanalysis of 14 studies including 46,637 patients, aged 
71.7 years, showed that AF was associated with a significant 
increase in dementia overall (odds ratio - OR 2.0, p <0.0001), 
albeit with substantial heterogeneity.6 When stratified by 
participants, the association was significant (with little hetero-
geneity) in studies focusing solely on patients with stroke (7 
studies, OR 2.4, p <0.001), and of borderline significance (with 
substantial heterogeneity) for studies in broader populations 
(7 studies, OR 1.6, p=0.05). For conversion of mild cognitive 
impairment to dementia, one study showed a significant as-
sociation with AF (OR 4.6). The authors concluded that there 
is consistent evidence supporting an association between AF 
and increased incidence of dementia in patients with stroke, 
but there remains considerable uncertainty about any link in 
the broader population. 
According to another metanalysis of 8 studies with 77,668 
elderly patients, aged 61-84 years, with normal cognitive 
function at baseline, of whom 11,700 (15%) had AF, 4773 of 
73,321 (6.5%) patients developed dementia at a mean follow-
up of 7.7±9.1 years.20 At pooled analysis adjusted for baseline 
confounders and covariates, AF was independently associated 
with increased risk of incident dementia (HR = 1.42, P <.001). 
The authors concluded that AF is independently associated 
with increased risk of dementia. 
In a recent review of studies comparing the incidence of 
cognitive impairment and/or dementia in patients with/without 
AF, 8 out of 11 studies (3 cross-sectional, 2 case-control and 3 
prospective cohorts) reported an association between cognitive 
decline and AF, but the risk varied.7 Among cross-sectional 
studies, patients with AF had a 1.7 to 3.3 greater risk of cog-
nitive impairment, and a 2.3-fold increased risk of dementia, 
compared to patients in sinus rhythm. 
According with another meta-analysis of 21, albeit hetero-
geneous, studies, AF was significantly associated with a higher 
risk of cognitive impairment independent of stroke history 
(relative risk - RR=1.34), in patients with first or recurrent 
stroke (RR=2.7) and in a broader population of patients with 
or without a history of stroke (RR=1.4).21 Limiting the analy-
sis to prospective studies yielded similar results (RR=1.36). 
Restricting the analysis to studies of dementia eliminated the 
significant heterogeneity (P value =0.137) but did not alter 
the pooled estimate substantially (RR=1.38). The authors 
concluded that evidence suggests that AF is associated with 
a higher risk of cognitive impairment and dementia, with or 
without a history of clinical stroke. 
One should also keep in mind some conflicting results. 
According with a prospective 9-year follow-up population-
based study in Finland, among 553 subjects (92% of the total 
population) aged ≥85 years, AF was significantly associated 
with stroke at baseline (32% vs 16.7%; P <0.001).22 Dementia 
at baseline was significantly associated with age, clinical stroke, 
and the presence of apolipoprotein E epsilon4 allele, but 
not with sex, education, or vascular risk factors. The authors 
concluded that AF is a significant and preventable risk factor 
for stroke but not for dementia in the very old. Similarly in a 
prospective longitudinal cohort study of 362 men and women 
aged >60,23 there were no clinically important differences in 
cognitive function between baseline and follow-up at 1 and 3 
years, between 174 AF cases and 188 controls in sinus rhythm, 
nor between subgroups on aspirin, warfarin or neither.
However, accumulating data linking AF to not just mild 
cognitive impairment but to more advanced cognitive dysfunc-
tion (dementia) remain worrisome. A large cohort study indi-
cated that among 37,025 individuals from the Intermountain 
Heart Collaborative Study database (mean age 61±18 years),24 
a total of 10,161 (27%) developed AF and 1,535 (4.1%) devel-
oped dementia (179 vascular dementia, 321 senile dementia, 
347 Alzheimer’s, 688 nonspecified) during a 5-year follow-up. 
Patients with dementia were older with higher rates of hyper-
tension, coronary artery disease, renal failure, heart failure, 
and prior strokes. In age-based analysis, AF independently 
was significantly associated with all dementia types, with the 
highest risk in the younger group (<70). More importantly, 
in patients with dementia, AF was associated with a marked 
increased risk of mortality (hazard ratio ~1.4; P <0.0001).
E t I O L O G y
A plethora of etiologies of cognitive impairment and 
dementia have been implicated in a variety of clinical condi-
tions, among which vascular contributions predominate,25 
but non-vascular causes are also important. Unfortunately, a 
5-10% prevalence of dementia in affluent countries has been 
recognized in people ≥65 years of age.25 Even more impor-
tantly, in 2002, an estimated 5.4 million people (22.2%) in the 
United States aged ≥71 years had cognitive impairment without 
dementia,26 while both ends of the spectrum are associated 
with excess mortality.8 The most important cerebrovascular 
pathology that contributes to cognitive impairment is cerebral 
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infarcts and AF is a common source and cause of cerebral 
thrombo-embolism. However, cognitive decline has also been 
noted even in the absence of a clinically manifest stroke.
Silent brain infarction is often found in patients with AF 
and has been proposed as possibly implicated in cognitive 
decline (Table 1). A group of 103 neurologically asymptomatic 
patients (76 men, aged 63±10 years) with nonvalvular AF 
were screened for silent brain infarction with MRI and also 
underwent transesophageal echocardiography (TEE) before 
transcatheter AF ablation (76 men; mean age 63 ± 10 years).27 
A total of 31 (30%) patients showed silent brain infarction on 
brain MRI. Most lesions were multiple (61%) and small (<15 
mm) in diameter (84%). Patients with silent brain infarction 
had a higher prevalence of left atrial abnormalities (45% vs 
14%; P <.001) and complex aortic arch plaques (45% vs 7%; 
P <0.001) compared with those without silent brain infarc-
tion. In multivariate analysis, left atrial abnormalities (odds 
ratio 4.13; P=0.014) and complex aortic arch plaques (odds 
ratio 4.82; P=0.024) were independent predictors of silent 
brain infarction, suggesting that microembolization of small 
thrombi derived from the fibrillating left atrium or advanced 
aortic atherosclerotic lesions may be important causes of silent 
brain infarction in patients with nonvalvular AF. 
The prevalence of silent cerebral infarctions and their 
association with AF was estimated in a systematic review and 
meta-analysis of 11 studies including 5317 patients (aged 50 
to 83.6 years) with AF and no clinical history of stroke or 
prosthetic valves.28 When computed tomography and MRI 
studies were combined, AF was associated with silent cerebral 
infarctions (odds ratio - OR, 2.62). This association was in-
dependent of AF type (paroxysmal vs persistent). The overall 
prevalence of silent cerebral infarction lesions, reported in 17 
studies, among patients with AF was 40% on MRI and 22% 
on computed tomography. The authors concluded that AF is 
associated with more than a 2-fold increase in the odds for 
silent cerebral infarctions.
The association of incident AF with cognitive decline was 
examined in stroke-free individuals, stratified by subclinical 
cerebral infarcts on brain MRI scans in the Atherosclerosis 
Risk in Communities (ARIC) Study.29 During follow-up, there 
were 48 incident AF events among 935 stroke-free individuals 
(aged 61.5±4.3 years; 62% women; 51% black). Incident AF 
was associated with greater annual average rate of cognitive 
decline tested by digit symbol substitution (-0.77; P=0.054) and 
word fluency (-0.80; P=0.048). Among participants without sub-
clinical cerebral infarcts on brain MRI scans, incident AF was 
not associated with cognitive decline. The authors concluded 
that the association of incident AF with cognitive decline in 
stroke-free individuals can be explained by the presence or 
development of subclinical cerebral infarcts, raising the possibil-
ity that anticoagulation might prevent cognitive decline in AF. 
The possibility of exposure to chronic microembolism or 
microbleeds resulting in repetitive cerebral injury that is mani-
fest by cognitive decline, has been suggested by a study examing 
the association of low percentage of time in the therapeutic 
range (TTR) to higher risk for dementia due to under- or 
over-anticoagulation. Dementia was diagnosed in 109 patients 
(4.2%) (senile: 37 or 1.4%; vascular: 8 or 0.3%; Alzheimer: 
64 or 2.5%) among 2605 AF patients (age 73.7±10.8 years, 
54% male) anticoagulated with warfarin.30 The percent TTR 
averaged 63.1±21.3, with percent INR <2.0: 25.6%±17.9% 
and percent INR >3.0: 16.2%±13.6%. After adjustment, 
decreasing categories of percent TTR were associated with 
increased dementia risk (vs >75%): <25%: hazard ratio - HR 
5.34, P <0.0001; 26%-50%: HR 4.10, P <0.0001; and 51%-
75%: HR=2.57, P=0.001. The authors concluded that quality 
of anticoagulation management represented as percent TTR 
among AF patients without dementia was associated with 
dementia incidence. 
Thus, it is apparent that AF produces cognitive decline 
independent of stroke, suggesting additional effects of AF on 
the brain. In a cross-sectional analysis of 4251 nondemented 
participants (mean age, 76±5 years) in the population-based 
AGES-Reykjavik Study, 330 participants had AF.31 Partici-
pants with AF had lower total brain volume on MRI compared 
with those without AF (P <0.001). The association was 
stronger with persistent/permanent than paroxysmal AF and 
with increased time from the first diagnosis of the disease. 
Of the brain tissue volumes, AF was associated with lower 
volume of gray and white matter hyperintensities (P <0.001 
and P=0.008, respectively), but not of white matter hyperin-
tensities (P=0.49). Participants with AF scored lower on tests 
of memory. The authors concluded that AF is associated with 
smaller brain volume, and the association is stronger with in-
creasing burden of the arrhythmia. These findings suggest that 
AF has a cumulative negative effect on the brain independent 
of cerebral infarcts. The difference in total brain volume be-
tween individuals with and without AF equals a year and a half 
of normal loss of brain volume. In their discussion the authors 
consider the possible explanatory mechanisms for their find-
ings. The association between AF and brain atrophy and lower 
performance on memory tests could be attributed to increased 
comorbidity and cerebral infarcts in the AF population. AF 
causes multiple microembolisms and microinfarcts to the brain 
and subsequent atrophy. Additionally, cerebral hypoperfu-
sion, attributable to beat-to-beat variation in stroke volume, 
also may play a part. Patients with persistent/permanent AF 
may have more cerebral hypoperfusion than those with only 
paroxysmal AF, explaining the finding of greater brain atrophy 
encountered in patients with persistent/permanent AF.
The hypotheses that hemostatic function is altered in 
subjects with AF who develop dementia, and that long-term 
warfarin anticoagulation is protective against this complication 
were tested in an observational cohort study of 218 AF patients, 
of whom 145 (66%) were prescribed warfarin.32 Forty-nine 
(22%) met criteria for dementia after 3 years’ follow-up. D-
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dimer, prothrombin fragment 1+2 and thrombin-antithrombin 
complexes levels were higher in AF subjects with dementia 
compared with those without (P=0.003-0.008). These asso-
ciations became of borderline statistical significance follow-
ing adjustment for age. Logistic regression showed a trend 
towards warfarin use being independently associated with 
reduced prevalence of dementia (odds ratio 0.52, P=0.08). 
The authors concluded that there is increased thrombin gen-
eration and fibrin turnover in subjects with AF and dementia 
compared with those without dementia. Long-term warfarin 
use may be protective against the development of dementia 
in subjects with AF. 
The role of ventricular rate response on the incidence of 
dementia in elderly subjects with cognitive impairment and 
AF was examined in 358 cognitively impaired elderly subjects 
with and without AF, stratified in low/high (<50/>90) and 
moderate (>50/<90 bpm) ventricular rate response.33 Over 
10 years, among these cognitively impaired subjects, 135 
(37.7%) progressed to dementia, 33 in the presence (75%) 
and 102 (32.5%) in the absence of AF (p <0.001). Multivariate 
analysis showed that AF was a strong predictor of dementia 
(hazard ratio - HR = 4.10; p <0.001). Importantly, low/high 
ventricular rate response (<50/>90 bpm) was predictive of 
dementia in the presence (HR=7.70, p=0.03) but not in the 
absence (HR = 1.85; p=0.152) of AF. The authors concluded 
that AF predicts dementia in elderly subjects with cognitive 
impairment, and ventricular rate response seems to play a 
key role in the incidence of dementia in cognitively impaired 
elderly subjects with AF. 
Experimental data indicate that vascular oxidative stress 
and inflammation are key pathogenic factors in neurovascular 
dysfunction,25 and there is evidence that AF is associated with 
activated inflammatory mechanisms (reflected by an increase 
in various inflammatory markers), linked to the prothrombotic 
state of AF.34 Finally, there is information that vitamin K is an 
important nutritional factor of cognitive health during aging 
and animal data suggest that deficient vitamin K is a potential 
mechanism of cognitive impairment,35 as lifetime consump-
tion of a low-vitamin K diet is associated with higher levels of 
ceramides in the hippocampus, a key brain region in spatial 
memory and navigation; importantly, several studies have 
reported elevated levels of ceramides in neurodegenerative 
disease such as Alzheimer’s disease. This information has 
raised concerns about the role of vitamin K antagonists in 
patients with AF and cognitive impairment, which contradicts 
the protective role of anticoagulants in thrombo-embolic com-
plications and their presumed benefit in cognition that these 
agents are expected to confer in AF patients. 
I N t E r v E N t I O N s
Firstly, according to the AF Follow-up Investigation of 
Rhythm Management (AFFIRM) functional status substudy, 
cognitive function was similar in rate-control and rhythm-
control strategies.36 Secondly, although one would have 
expected that oral anticoagulants would confer a protective 
effect in AF patients from cognitive decline, the data remain 
inconclusive.32,37 According to a randomized controlled trial, 
the Birmingham AF Treatment of the Aged (BAFTA) study, 
there is no evidence that anticoagulation confers clinically 
important protection over aspirin against cognitive decline 
in AF in the first 33 months of treatment other than that 
provided by preventing clinical stroke.37 Indeed, among 973 
patients with AF aged ≥75 years assigned to warfarin (n=488) 
or low-dose aspirin (n=485), there was no difference in cogni-
tive function between the two groups at 9 or 21 months. At 
33-month follow-up, there was a nonsignificant difference of 
0.56 on adjusted analysis in favor of warfarin that decreased 
to 0.49 after multiple imputation. 
A concern has been raised whether vitamin K antagonists 
(VKAs) may further contribute to cognitive dysfunction, due to 
the potential role of vitamin K in brain physiology, as already 
mentioned, and a suggestion that its deficiency may induce cog-
nitive decline. A geriatric study comprising 267 older patients 
(aged 83.4±8.1 years; 57% female) indicated that compared 
with participants without cognitive impairment (n=70), those 
with compromised cognition used more frequently VKAs 
(p=0.038).38 The risk of cognitive impairment was 15% higher 
with VKAs; using VKAs was independently associated with 
cognitive impairment (adjusted odds ratio=17.4, p=0.028). 
Taking into consideration this latter caveat, it is bestowed 
upon future comparative trials to deduce any differential ef-
fect of the newer non-vitamin K anticoagulants on cognition 
in patients with AF. 
A small group of 34 older patients with AF were treated 
with intensive lipid-lowering therapy with atorvastatin 40 mg 
and ezetimibe 10 mg (n=17), or placebo (n=17).39 Significant 
reductions in inflammatory markers were recorded in the 
treatment group compared to placebo. Reduction in plasma 
concentration of inflammatory markers correlated significantly 
with improvement in the neurocognitive functions memory 
and speed. Loss of volume in amygdala and hippocampus, as 
determined by MRI, was reduced in the treatment arm, sta-
tistically significant for left amygdala. The authors concluded 
that therapy with atorvastatin and ezetimibe can modify the 
decline of neurocognitive function, and the loss of volume in 
certain cerebral areas in older patients with AF. 
The risk of non-vascular dementia was compared between 
statin (n=51,253 AF patients aged ≥60 years who had received 
statin treatment) and control groups (n=205,012 age- and 
gender-matched AF patients not on statin) (data from the 
National Health Insurance Research Database of Taiwan).40 
During follow-up, 17,201 patients experienced non-vascular 
dementia. The annual incidence of non-vascular dementia was 
lower in the statin group than in the control group (1.89% vs. 
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2.20%; p<0.001). Statin use exhibited a protective effect on 
the occurrence of non-vascular dementia, with an adjusted 
hazard ratio (HR) of 0.832. Among statin types, the use of 
rosuvastatin was associated with the largest risk reduction 
(adjusted HR=0.661). The authors concluded that statin use 
conferred a lower risk of non-vascular dementia in AF. Use 
of more potent statin and longer exposure duration may be 
associated with greater benefits.
According with an observational study, those (n=4,212) 
who underwent radiofrequency ablation therapy for AF, which 
currently offers a best available rhythm control strategy for 
AF, had significantly lower risk for dementia than age/gender 
matched AF patients who did not have an ablation (n=16,848) 
and similar to the risk of age/gender matched controls without 
AF (n=16,848).41 Of the 37,908 patients, aged 65±13 years, 
5,667 (14.9%) died, 1,296 (3.4%) had a stroke, and 1,096 
(2.9%) were hospitalized for heart failure over >3 years of 
follow-up. AF ablation patients had a lower risk of death and 
stroke in comparison to AF patients without ablation. Alzhei-
mer’s dementia occurred in 0.2% of the AF ablation patients 
compared to 0.9% of the AF no ablation patients and 0.5% 
of the no AF patients (P <0.0001). Other forms of dementia 
were also reduced significantly in those treated with ablation. 
Compared to patients with no AF, AF ablation patients had 
similar long-term rates of death, dementia, and stroke. The au-
thors concluded that AF ablation patients have a significantly 
lower risk of death, stroke, and dementia in comparison to AF 
patients without ablation. 
The above results contrast with reports indicating that 
the ablation procedure itself may be associated with micro-
infarcts affecting patients’ memory.42,43 According to a small 
study, among 21 AF patients undergoing ablation, 3 (14%) 
developed new ischemic lesions detected on MRI shortly after 
intervention (clinically symptomatic in 1 and clinically silent 
in 2).42 In contrast to the control group (non-AF controls, 
n=23) and in covariance of baseline performance, the ablation 
group showed worse neuropsychological outcome in verbal 
memory at 3 months post-procedurally. The authors concluded 
that adverse neuropsychological changes after AF ablation 
may represent cerebral complications of this procedure. In 
a larger study comprising 90 patients with AF undergoing 
ablation, post-operative neurocognitive dysfunction occurred 
in 13%-20% at the 3-month follow-up compared with 0% in 
the non-ablation AF group.43 No studies comparing different 
modes of AF ablation (e.g. radiofrequency versus cryo-balloon 
ablation) and their effect on neurocognitive function have 
been conducted to date.
Finally, other modes of AF management, such as surgical 
or percutaneous closure of left atrial appendage, have not been 
explored whether they have an effect on cognition. However, 
the problem of cognitive impairment appears to be real and of 
utmost importance to consider in the AF patient population, 
and recommendations have been put forth advocating that 
all patients with AF be screened for cognitive decline and all 
patients with cognitive decline be screened for AF.5
c O N c L U s I O N
There appears to be convincing evidence accumulated 
todate suggesting that AF, in addition to its known thrombo-
embolic risk, is a risk factor for a whole spectrum of cognitive 
impairment by a variety of mechanisms, further contributing 
to morbidity and mortality. Screening for both conditions is 
strongly advisable (Figure 1).5,10 Preliminary evidence indicates 
that anticoagulation, rhythm and rate control strategies may 
have a significant protective action, particularly at the early 
stages of the disease when mild cognitive impairment may still 
be a treatable condition,44 although future randomized control 
studies are needed to further establish such claim.
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